Finding Candidate Drugs for Hepatitis C Based on Chemical-Chemical and Chemical-Protein Interactions

被引:35
作者
Chen, Lei [1 ]
Lu, Jing [2 ]
Huang, Tao [3 ]
Yin, Jun [1 ]
Wei, Lai [1 ]
Cai, Yu-Dong [4 ]
机构
[1] Shanghai Maritime Univ, Coll Informat Engn, Shanghai, Peoples R China
[2] Yantai Univ, Sch Pharm, Dept Med Chem, Yantai, Shandong, Peoples R China
[3] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA
[4] Shanghai Univ, Inst Syst Biol, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
ANTIVIRAL TREATMENT; VIRUS-INFECTION; PREDICTION; THERAPY; REPLICATION; COMBINATION; INTERFERON; CELGOSIVIR; DRUGBANK; MACHINE;
D O I
10.1371/journal.pone.0107767
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Hepatitis C virus (HCV) is an infectious virus that can cause serious illnesses. Only a few drugs have been reported to effectively treat hepatitis C. To have greater diversity in drug choice and better treatment options, it is necessary to develop more drugs to treat the infection. However, it is time-consuming and expensive to discover candidate drugs using experimental methods, and computational methods may complement experimental approaches as a preliminary filtering process. This type of approach was proposed by using known chemical-chemical interactions to extract interactive compounds with three known drug compounds of HCV, and the probabilities of these drug compounds being able to treat hepatitis C were calculated using chemical-protein interactions between the interactive compounds and HCV target genes. Moreover, the randomization test and expectation-maximization (EM) algorithm were both employed to exclude false discoveries. Analysis of the selected compounds, including acyclovir and ganciclovir, indicated that some of these compounds had potential to treat the HCV. Hopefully, this proposed method could provide new insights into the discovery of candidate drugs for the treatment of HCV and other diseases.
引用
收藏
页数:6
相关论文
共 34 条
[1]  
[Anonymous], 1990, M 196 1988 LOS ANG C
[2]   Fluvastatin inhibits hepatitis C replication in humans [J].
Bader, Ted ;
Fazili, Javid ;
Madhoun, Mohammed ;
Aston, Christopher ;
Hughes, Diane ;
Rizvi, Syed ;
Seres, Ken ;
Hasan, Muhammad .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (06) :1383-1389
[3]   Treatment of chronic hepatitis C: A systematic review [J].
Chander, G ;
Sulkowski, MS ;
Jenckes, MW ;
Torbenson, MS ;
Herlong, HF ;
Bass, EB ;
Gebo, KA .
HEPATOLOGY, 2002, 36 (05) :S135-S144
[4]   A hybrid method for prediction and repositioning of drug Anatomical Therapeutic Chemical classes [J].
Chen, Lei ;
Lu, Jing ;
Zhang, Ning ;
Huang, Tao ;
Cai, Yu-Dong .
MOLECULAR BIOSYSTEMS, 2014, 10 (04) :868-877
[5]   Prediction of drug target groups based on chemical-chemical similarities and chemical-chemical/protein connections [J].
Chen, Lei ;
Lu, Jing ;
Luo, Xiaomin ;
Feng, Kai-Yan .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2014, 1844 (01) :207-213
[6]   Predicting Anatomical Therapeutic Chemical (ATC) Classification of Drugs by Integrating Chemical-Chemical Interactions and Similarities [J].
Chen, Lei ;
Zeng, Wei-Ming ;
Cai, Yu-Dong ;
Feng, Kai-Yan ;
Chou, Kuo-Chen .
PLOS ONE, 2012, 7 (04)
[7]   New developments in the antiviral treatment of hepatitis C [J].
de Bruijne, J. ;
Weegink, C. J. ;
Jansen, P. L. M. ;
Reesink, H. W. .
VOX SANGUINIS, 2009, 97 (01) :1-12
[8]   Hepatitis C virus infection protein network [J].
de Chassey, B. ;
Navratil, V. ;
Tafforeau, L. ;
Hiet, M. S. ;
Aublin-Gex, A. ;
Agaugue, S. ;
Meiffren, G. ;
Pradezynski, F. ;
Faria, B. F. ;
Chantier, T. ;
Le Breton, M. ;
Pellet, J. ;
Davoust, N. ;
Mangeot, P. E. ;
Chaboud, A. ;
Penin, F. ;
Jacob, Y. ;
Vidalain, P. O. ;
Vidal, M. ;
Andre, P. ;
Rabourdin-Combe, C. ;
Lotteau, V. .
MOLECULAR SYSTEMS BIOLOGY, 2008, 4 (1)
[9]   MAXIMUM LIKELIHOOD FROM INCOMPLETE DATA VIA EM ALGORITHM [J].
DEMPSTER, AP ;
LAIRD, NM ;
RUBIN, DB .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-METHODOLOGICAL, 1977, 39 (01) :1-38
[10]   New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication [J].
Himmelsbach, K. ;
Sauter, D. ;
Baumert, T. F. ;
Ludwig, L. ;
Blum, H. E. ;
Hildt, E. .
GUT, 2009, 58 (12) :1644-1653